Kenvue Inc. (KVUE)

NYSE: KVUE · Real-Time Price · USD
20.71
+0.17 (0.83%)
At close: Aug 29, 2025, 4:00 PM
20.80
+0.09 (0.43%)
After-hours: Aug 29, 2025, 7:00 PM EDT
0.83%
Market Cap39.74B
Revenue (ttm)15.14B
Net Income (ttm)1.42B
Shares Out 1.92B
EPS (ttm)0.74
PE Ratio27.98
Forward PE19.32
Dividend$0.82 (3.96%)
Ex-Dividend DateAug 13, 2025
Volume10,307,449
Open20.55
Previous Close20.54
Day's Range20.50 - 20.76
52-Week Range19.75 - 25.17
Beta0.79
AnalystsBuy
Price Target24.38 (+17.72%)
Earnings DateAug 7, 2025

About KVUE

Kenvue Inc. operates as a consumer health company in the United States, Europe, the Middle East, Africa, Asia-Pacific, and Latin America. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee’s, ORSLTM, Rhinocort, Calpol, and Zyrtec brands. Its Skin Health and Beauty segment provides face and body care, hair, sun, and other... [Read more]

IPO Date May 4, 2023
Employees 22,000
Stock Exchange NYSE
Ticker Symbol KVUE
Full Company Profile

Financial Performance

In 2024, Kenvue's revenue was $15.46 billion, an increase of 0.07% compared to the previous year's $15.44 billion. Earnings were $1.03 billion, a decrease of -38.10%.

Financial Statements

Analyst Summary

According to 12 analysts, the average rating for KVUE stock is "Buy." The 12-month stock price target is $24.38, which is an increase of 17.72% from the latest price.

Price Target
$24.38
(17.72% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Best Dividend Aristocrats For September 2025

Dividend Aristocrats have shown mixed 2025 performance, with some delivering double-digit gains and others lagging, but overall stability remains a hallmark. Dividend growth is robust, with 53 of 69 A...

5 days ago - Seeking Alpha

Kenvue Can't Be Written Off Yet

Kenvue's fundamental performance looks disastrous, with revenue and margins going in the wrong direction. In that context, a 20x-plus multiple to 2025 adjusted EPS looks far too high. But a new board,...

14 days ago - Seeking Alpha

Kenvue attracts share purchase by activist investor Sachem Head

Band-Aid and Tylenol maker Kenvue attracted the attention of another activist investor in the second quarter, with Sachem Head Capital Management reporting that it bought into the stock.

17 days ago - Reuters

Kenvue, Inc. (KVUE) Q2 2025 Earnings Call Transcript

Kenvue, Inc. (NYSE:KVUE) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Amit Banati - Chief Financial Officer Kirk L. Perry - Interim CEO & Director Sofya Tsinis - He...

25 days ago - Seeking Alpha

Kenvue meets profit estimates amid strategic review

Kenvue reported a second-quarter profit largely in line with Wall Street estimates on Thursday, amid a strategic review at the consumer health company.

25 days ago - Reuters

Kenvue Reports Second Quarter 2025 Results

SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced financial results for the second quarter ended June 29, 2025. “Kenvue has a strong portfolio of world-class, category-defining b...

25 days ago - Business Wire

Should You Buy Kenvue Stock At $22?

Although there has been a recent increase of 21% that aligns with the broader market gains, Kenvue (NYSE: KVUE) offers limited investment appeal at its current valuations. Our thorough analysis encomp...

27 days ago - Forbes

Kenvue Increases Quarterly Cash Dividend

SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced its Board of Directors declared a quarterly dividend of $0.2075 per share on its common stock, which represents a 1.2 percent in...

4 weeks ago - Business Wire

20 Kiplinger July Dividend Favorites: No Cigars

Dividend stocks are regaining appeal as interest rates fall, offering higher returns and lower risk compared to non-dividend payers over the long term. Top Kiplinger dividend 'dogs' are projected to d...

Other symbols: APDBDXDUKEPDGSHDJNJ
5 weeks ago - Seeking Alpha

Kenvue to Announce Second Quarter 2025 Results on August 7, 2025

SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) will announce its second quarter 2025 financial results before the market opens on August 7, 2025. The company will host a conference call and w...

5 weeks ago - Business Wire

Kenvue stock rises on CEO exit as company launches strategic review and warns of lower sales

Kenvue, the Johnson & Johnson spinoff that owns brands such as Tylenol and Benadryl, announced Monday that Chief Executive Officer Thibaut Mongon has stepped down. Kenvue shares were up by more than 6...

7 weeks ago - Invezz

Kenvue Seeks Its Own Band-Aid With CEO Departure and Strategic Review. The Stock Rises.

The company, formerly part of Johnson & Johnson, says it is taking steps ‘to accelerate profitable growth.'

7 weeks ago - Barrons

Kenvue CEO steps down

Tylenol maker Kenvue said on Monday Thibaut Mongon had stepped down as chief executive officer and board member.

7 weeks ago - Reuters

Kenvue Announces CEO Transition and Actions to Unlock Shareholder Value

SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced that its Board of Directors is implementing a set of actions to enable the Company to unlock shareholder value and reach its ful...

7 weeks ago - Business Wire

69 June Aristocrats: 1 To Buy

Five of the ten lowest-priced S&P 500 Dividend Aristocrats are currently attractive buys, offering high yields and fair valuations for income investors. Analyst forecasts suggest potential net gains o...

2 months ago - Seeking Alpha

Kenvue mulls sale of some skin health and beauty brands, sources say

Kenvue is exploring the sale of some of its skin health and beauty brands, four people familiar with the matter said on Thursday, as the consumer health firm prunes an underperforming business segment...

2 months ago - Reuters

INVESTOR NOTICE: Kaskela Law LLC Announces Investigation of Kenvue Inc. and Encourages Long-Term Kenvue Investors to Contact the Firm - KVUE

PHILADELPHIA, PA / ACCESS Newswire / June 9, 2025 / Kaskela Law LLC announces that it is investigating potential breach of fiduciary duty claims concerning Kenvue Inc. (NYSE:KVUE) on behalf of the com...

3 months ago - Accesswire

Kenvue: Steady Consumer Health Play; Initiate With 'Buy'

I initiate Kenvue with a 'Buy' rating and a $26 fair value, citing its iconic brands and steady dividend appeal. Kenvue's global operations, diversified product lines, and strong R&D enable resilience...

3 months ago - Seeking Alpha

June's Dividend Kings: 3 Ideal Buys In 25 "Safer" Dogs

Most Dividend Kings are currently overpriced, but six offer fair value where annual dividends from $1,000 invested exceed their share price. Three top-yield Dividend Kings—Altria, Northwest Natural, a...

Other symbols: ABBVABMADMADPBDXBKHCWT
3 months ago - Seeking Alpha

Benadryl, Band-Aid parent says tariffs and late allergy season are hurting its business

Kenvue Chief Executive Thibaut Mongon said the consumer continues to be under pressure.

3 months ago - Market Watch

Kenvue Debuts on Fortune 500 List

SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE), maker of consumer health products like Tylenol®, Neutrogena® and Listerine®, today announced it has made the prestigious Fortune 500 list for t...

3 months ago - Business Wire

Kenvue Announces Participation in Deutsche Bank's dbAccess Global Consumer Conference

SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE), the maker of iconic brands such as Neutrogena®, Listerine®, Aveeno®, and Tylenol®, today announced the Company's participation in Deutsche Bank...

3 months ago - Business Wire

69 May Aristocrats: Buy 1 Of 38 "Safer" Dividend Dogs

Many S&P 500 Dividend Aristocrats remain overvalued, but select high-yield 'Dogs' like Realty Income and Amcor offer attractive entry points for income investors. Analyst forecasts suggest the top ten...

3 months ago - Seeking Alpha

Moody's U.S. Debt Downgrade: Stocks Poised To Benefit

Corporations play a vital and often benevolent role in capitalist societies, supporting economic growth and innovation with more conservative balance sheets than their governments. Microsoft, Apple an...

Other symbols: AALAAPLCCLCUKFGMGOOG
3 months ago - Seeking Alpha

Third Point details stakes in U.S. Steel, Kenvue in filing

Billionaire investor Daniel Loeb's hedge fund Third Point on Thursday detailed the size of its stakes in U.S. Steel and Kenvue , companies that shareholders hope will soon benefit from being bought by...

Other symbols: X
3 months ago - Reuters